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Abstract: Bilirubin, an endogenous antioxidant, may play a protective role in cancer development. 
We applied two-sample Mendelian randomization to investigate whether genetically raised biliru-
bin levels are causally associated with the risk of ten cancers (pancreas, kidney, endometrium, 
ovary, breast, prostate, lung, Hodgkin’s lymphoma, melanoma, and neuroblastoma). The number 
of cases and their matched controls of European descent ranged from 122,977 and 105,974 for breast 
cancer to 1200 and 6417 for Hodgkin’s lymphoma, respectively. A total of 115 single-nucleotide 
polymorphisms (SNPs) associated (p < 5 × 10−8) with circulating total bilirubin, extracted from a 
genome-wide association study in the UK Biobank, were used as instrumental variables. One SNP 
(rs6431625) in the promoter region of the uridine-diphosphoglucuronate glucuronosyltransfer-
ase1A1 (UGT1A1) gene explained 16.9% and the remaining 114 SNPs (non-UGT1A1 SNPs) ex-
plained 3.1% of phenotypic variance in circulating bilirubin levels. A one-standarddeviation incre-
ment in circulating bilirubin (≈ 4.4 µmol/L), predicted by non-UGT1A1 SNPs, was inversely associ-
ated with risk of squamous cell lung cancer and Hodgkin’s lymphoma (odds ratio (OR) 0.85, 95% 
confidence interval (CI) 0.73–0.99, P 0.04 and OR 0.64, 95% CI 0.42–0.99, p 0.04, respectively), which 
was confirmed after removing potential pleiotropic SNPs. In contrast, a positive association was 
observed with the risk of breast cancer after removing potential pleiotropic SNPs (OR 1.12, 95% CI 
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1.04–1.20, p 0.002). There was little evidence for robust associations with the other seven cancers 
investigated. Genetically raised bilirubin levels were inversely associated with risk of squamous cell 
lung cancer as well as Hodgkin’s lymphoma and positively associated with risk of breast cancer. 
Further studies are required to investigate the utility of bilirubin as a low-cost clinical marker to 
improve risk prediction for certain cancers. 
Keywords: bilirubin; UGT1A1; Mendelian randomization; cancer risk 
 
1. Introduction 
Cancer is a major cause of morbidity and mortality globally, and the number of new 
cancer cases is expected to increase further over the next decades (CDC, 2020). In 2018, 
there were over 18 million new cancer cases and nine million cancer-related deaths [1]. 
Cancer-promoting inflammation is an enabling characteristic of cancer development, 
and inflammatory cells can also release reactive oxygen species [2]. A major cause of can-
cer is damage to DNA as a result of oxidative stress, mainly due to excess reactive oxygen 
species, antioxidants depletion, or both [3]. 
Bilirubin, a metabolic by-product of hemoglobin breakdown, is one of the most po-
tent endogenous antioxidants of the human body and also has substantial anti-inflamma-
tory properties [4–7]. Therefore, bilirubin may play a preventive role in cancer develop-
ment. Blood levels of bilirubin are under genetic control via expression of uridine-diphos-
phoglucuronate glucuronosyltransferase1A1 (UGT1A1) in the liver, which converts insol-
uble bilirubin into a more water-soluble form for renal and biliary excretion [8]. Individ-
uals homozygous for seven thymine–adenine (TA)-repeats (7/7) at the UGT1A1*28 locus 
have decreased enzyme activity, which leads to a less effective glucuronidation and mod-
erately higher than normal blood levels of bilirubin (known as Gilbert’s syndrome, GS) 
[9,10]. 
The seven TA-repeats allele of UGT1A1*28 polymorphism underlying GS was inves-
tigated in relation to cancers of the endometrium [11], ovary [12], lung [13,14], breast [15], 
and prostate [16]. However, results of these studies were inconclusive, did not specifically 
investigate bilirubin as a putative cancer risk factor, and had limited sample size (range 
of number of cases 129 to 310), with the exception of Horsfall et al., where an inverse as-
sociation was observed between genetically raised bilirubin levels and lung cancer risk 
among current smokers [14]. 
In this study, we investigated whether genetically raised circulating bilirubin levels 
are causally associated with risk of ten cancers using a Mendelian randomization (MR) 
approach. This technique uses genetic variation as instrumental variables [17], and in the 
absence of pleiotropy, an association between the genetic instruments and the outcome 
implies that the risk factor of interest may have a causal role in disease etiology (here: 
cancer risk) [18]. MR addresses unmeasured confounding (e.g., by smoking), which is a 
major limitation of observational studies [17]. The ten cancer types were investigated in 
large international consortia and selected based on previous evidence (cancers of the lung, 
ovary, endometrium, breast, and prostate) [11–16] or biological plausibility (pancreatic 
cancer, renal cell cancer, Hodgkin’s lymphoma, melanoma, and neuroblastoma). 
2. Materials and Methods 
In a two-sample MR approach, we first identified 115 single-nucleotide polymor-
phisms (SNPs) that were genome-wide associated (p < 5 × 10-8) with circulating total bili-
rubin levels in a genome-wide association study (GWAS) that included 317,639 individu-
als of European ancestry (white British) from the UK Biobank (UKB) (non-British white, 
South Asian, African, and East Asian GWASs were excluded based on a combination of 
self-identification and refinement using population-specific genotype principal 
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components) [19]. The UKB project, a long-term prospective cohort study, recruited about 
500,000 people aged between 40 and 69 years in 2006–2010 from across the UK [20]. The 
raw total bilirubin levels were adjusted for age, sex, the top 40 principal components for 
population stratification, recruitment center, indicators of socioeconomic status, and po-
tential technical confounders (blood and urine sampling time, fasting time, and sample 
dilution factor) [19]. SNPs were independently associated with total bilirubin levels, 
which were reflected by measures of linkage disequilibrium (LD R2 < 0.001). The SNPs 
with ambiguous strand codification (T-A or guanine-cytosine, G-C) were replaced by 
SNPs in LD R2 > 0.8 in European populations using the proxysnps R package. The summary 
statistics for the associations of SNP allele dosage with standardized bilirubin levels are 
shown in Table S1. 
One SNP (rs6431625) in the promoter region of the UGT1A1 gene in chromosome 2 
explained 16.9% of phenotypic variance in circulating total bilirubin levels, which was 
estimated as a function of the effect size for the risk factor in standard deviation units and 
the minor allele frequency [21]. This SNP was in strong linkage disequilibrium (LD R2 = 
0.74) with the UGT1A1*28 promoter TA-repeats polymorphism (rs3064744) [22]. The re-
maining 114 SNPs (non-UGT1A1 SNPs) explained 3.1% of the total bilirubin variance [22] 
and provided an F-statistic for the strength of the relationship between the genetic instru-
ment and the bilirubin levels of 89.1. The F-statistic is an estimation of the magnitude of 
the instrument bias (e.g., F-statistic <10 for the weak instruments) [23]. 
Second, ten cancer types were analyzed using genetic data that together summed up 
to a total of 336,110 cancer cases and 589,467 controls of European ancestry (Table 1). 
Cases and controls were individually matched in the original GWAS for each cancer, in-
cluding pancreatic cancer (overall and sex subgroups) [24–26], renal cell cancer (overall 
and sex subgroups) [27], lung cancer (overall, ever and never smokers subgroups, and 
histological subtypes of adenocarcinoma, squamous cell, and small cell) [28], ovarian can-
cer (overall and serous subgroup) [29], endometrial cancer [30], breast cancer (overall and 
estrogen receptor (ER) subgroups) [31], prostate cancer [32], Hodgkin’s lymphoma [33], 
melanoma, [34] and neuroblastoma [35]. To prevent weak instrument bias, these genetic 
data did not include samples from the UKB. Each contributing study was approved by 
the appropriate institutional review board/ethics committee. All participants provided in-
formed consent. 
Table 1. Summary information of cancer GWAS samples and power assessment. 
Cancer Type Subtype N Cases N Controls SNP Set Minimum Detectable OR 
Pancreatic cancer 
overall 7110 7264 UGT1A1 SNP 1.12/0.89 
    Non-UGT1A1 SNPs (n=113) 1.30/0.77 
men 3861 4056 UGT1A1 SNP 1.17/0.86 
      Non-UGT1A1 SNPs (n=113) 1.43/0.70 
women  3252 3268 UGT1A1 SNP 1.18/0.84 
    Non-UGT1A1 SNPs (n=113) 1.48/0.67 
Renal cell cancer 
overall 10,784 20,406 UGT1A1 SNP 1.08/0.92 
    Non-UGT1A1 SNPs (n=111) 1.21/0.83 
men 3227 4916 UGT1A1 SNP 1.17/0.86 
      Non-UGT1A1 SNPs (n=109) 1.43/0.70 
women 1992 3095 UGT1A1 SNP 1.22/0.82 
    Non-UGT1A1 SNPs (n=109) 1.58/0.63 
Lung cancer 
overall 29,266 56,450 UGT1A1 SNP 1.05/0.95 
    Non-UGT1A1 SNPs (n=109) 1.12/0.89 
ever smokers 23,223 16,964 UGT1A1 SNP 1.07/0.93 
    Non-UGT1A1 SNPs (n=109) 1.17/0.85 
never smokers 2355 7504 UGT1A1 SNP 1.17/0.85 
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    Non-UGT1A1 SNPs (n=109) 1.46/0.69 
adenocarcinoma 11,273 55,483 UGT1A1 SNP 1.07/0.93 
    Non-UGT1A1 SNPs (n=109) 1.18/0.85 
squamous cell 7426 55,627 UGT1A1 SNP 1.09/0.92 
    Non-UGT1A1 SNPs (n=109) 1.22/0.82 
small cell 2664 21,444 UGT1A1 SNP 1.15/0.87 
      Non-UGT1A1 SNPs (n=109) 1.39/0.72 
Ovarian cancer 
overall 25,509 40,941 UGT1A1 SNP 1.06/0.95 
    Non-UGT1A1 SNPs (n=111) 1.14/0.88 
serous 16,003 40,941 UGT1A1 SNP 1.07/0.94 
      Non-UGT1A1 SNPs (n=111) 1.16/0.86 
Breast cancer 
overall 122,977 105,974 UGT1A1 SNP 1.03/0.97 
    Non-UGT1A1 SNPs (n=112) 1.07/0.94 
Endometrial cancer 
  overall 12,906 108,979 UGT1A1 SNP 1.07/0.94 
      Non-UGT1A1 SNPs (n=110) 1.16/0.86 
Prostate cancer  
  overall 79,194 61,112 UGT1A1 SNP 1.04/0.96 
      Non-UGT1A1 SNPs (n=107) 1.09/0.92 
Hodgkin’s lymphoma 
  overall 1200 6417 UGT1A1 SNP 1.24/0.81 
      Non-UGT1A1 SNPs (n=91)  1.65/0.61 
Melanoma 
overall 1804 1026 UGT1A1 SNP 1.31/0.77 
     Non-UGT1A1 SNPs (n=75)  1.86/0.54 
Neuroblastoma 
overall 1627 3254 UGT1A1 SNP 1.23/0.81 
     Non-UGT1A1 SNPs (n=57)  1.62/0.62 
Abbreviations: N Number, OR odds ratio, SNP single nucleotide polymorphism. 
SNPs summary estimates (βcancer) were retrieved from these recently published 
GWAS results, which were obtained from: their cancer genetic consortia [27–32,36], the 
Genotypes and Phenotypes database (dbGaP) [37], public web repositories, and the MR-
Base platform [38]. 
Imputed SNPs were restricted based on imputed accuracy, and only SNPs with high 
imputation quality (R2 > 0.8) were selected for our analyses. SNPs summary statistics for 
genetic associations with risk of the ten cancers are shown in Table S1. 
Statistical Analyses 
A priori power calculations were performed for MR associations of nominal statistical 
significance (α<0.05) between both the UGT1A1 SNP and non-UGT1A1 SNPs, respec-
tively, and cancer risk; given the explained variance and the sample sizes for the different 
cancers, using the method proposed by Burgess et al. [39]. 
Estimated risk effects were obtained for each genetic variant, named Wald estimate 
(genetic effect on cancer risk [βcancer]/ genetic effect on total bilirubin levels [βbilirubin]). 
As the main MR approach used in the analyses of the large SNPs set, excluding the 
UGT1A1 SNP, the Wald estimates were combined in a single estimate through a likeli-
hood-based MR approach. This approach is considered to be the most robust under the 
general assumption for all MR methods regarding linear relationship between the expo-
sure and the outcome [40], which we assumed in the range of bilirubin variation reflected 
by these SNPs. 
The initial step in the sensitivity analyses was to apply the inverse-variance weighted 
(IVW) MR approach [41] and to assess the presence of outlier observations among the SNP 
Wald estimates using the MR pleiotropy residual sum and outlier (MR-PRESSO) test [42]. 
The MR-PRESSO approach identifies heterogeneity between SNP effects (pGlobal) as an ev-
idence of directional horizontal pleiotropy, identifies outlier SNPs, and tests if the pres-
ence of outliers is biasing the estimation of risk (pDistortion). 
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To evaluate the extent to which directional pleiotropy may affect the risk estimates, 
we used the intercept test within a MR-Egger weighted linear regression approach [43]. 
Moreover, the weighted median [21] and the modal-based estimate MR approaches [44] 
were applied to estimate the weighted median and the mode of the density distribution 
of the SNP estimates. Both methods are less sensitive to the presence of potentially invalid 
SNPs. Finally, we assessed whether pleiotropic SNPs, thus potentially violating the exclu-
sion restriction (horizontal pleiotropy) and the independence assumptions (no confound-
ers), were driving the association estimates. We looked up the genetic association results 
of bilirubin SNPs with other phenotypes in the GWAS Catalog database [45] and obtained 
MR estimates and performed sensitivity analyses excluding the SNPs reaching a genome-
wide threshold of association with other phenotypes. 
Analyses were performed stratified by sex for pancreatic and renal cell cancers, also 
by subtypes for lung, ovarian, and breast cancer. We did not account for multiple testing, 
since we had a strong prior hypothesis based on biological plausibility and applying a 
strict multiple testing correction would likely have been overly conservative given the 
non-independence of risk for many of the cancers tested [46]. 
Scatter plots were used to depict the genetic association on total bilirubin levels and 
cancer risk. All statistical analyses and plots were performed using Stata SE14 (Stata Cor-
poration, College Station, TX, USA) and R (MR-PRESSO, Two-Sample MR, gwasrapidd, and 
ggplot2; The R project). All statistical tests were two-tailed. 
3. Results 
The minimum odds ratios (OR) that our analyses were able to detect for the UGT1A1 
SNP and non-UGT1A1 SNPs, respectively, and each cancer are shown in Table 1. 
Each standard deviation (SD ≈ 4.4 µmol/L) increment in bilirubin levels predicted by 
rs6431625 in the UGT1A1 gene was not associated with risk of pancreatic cancer (OR per 
one-standard deviation, 1-SD 1.02; 95% of confidence interval (CI) 0.95–1.11), whereas 
higher bilirubin levels predicted by non-UGT1A1 SNPs showed an inverse association 
with pancreatic cancer overall (OR 0.74; 95% CI 0.61–0.89), with similar risk estimates 
among men and women (OR 0.75; 95% CI 0.58–0.96, and OR 0.73; 95% CI 0.55–0.97, per 1-
SD increment, respectively) (Figure 1A). However, after removing SNPs (n = 22) with po-
tential pleiotropy, these associations were attenuated toward the null (Table S2). The scat-
ter plot depicting the genetic associations of these instruments with bilirubin levels and 
with the risk of pancreatic cancer overall, and among men and women, including the like-
lihood-based MR estimate and its 95% CI, are shown in Figure S1A-C. 
Neither the UGT1A1 SNP nor the non-UGT1A1 SNPs were associated with risk of 
renal cell cancer in men and women combined (Figure 1A and Figure S1D-F); however, a 
suggestive inverse association was observed between bilirubin levels predicted by the 
non-UGT1A1 SNPs and renal cell cancer in men (OR 0.76; 95% CI 0.57–1.00). After remov-
ing potential pleiotropic SNPs (n = 22), these associations were attenuated toward the null 
(Table S2). 
Overall, we did not observe an association between bilirubin levels predicted by ei-
ther the UGT1A1 SNP or the non-UGT1A1 SNPs and lung cancer risk (OR per 1-SD 0.98; 
95% CI 0.94–1.02, by UGT1A1 SNP; and OR 0.91; 95% CI 0.83–1.00, by non-UGT1A1 SNPs) 
(Figure 1B). In stratified analyses, genetically raised bilirubin levels predicted by the non-
UGT1A1 SNPs, but not the UGT1A1 SNP, were inversely associated with lung cancer risk 
among individuals who ever smoked, squamous cell, and small cell lung cancer subtypes 
with ORs equal to 0.86; 95% CI 0.76–0.96, 0.85; 95% CI 0.73–0.99, and 0.77; 95% CI 0.61–
0.97, per 1-SD increment, respectively (Figure 1B). The scatter plots for bilirubin levels and 
lung cancer risk are shown in Figure S2. Among squamous cell carcinoma, the inverse 
associations were robust in terms of effect size to sensitivity analyses and after removing 
SNPs (n = 22) with potential pleiotropy (Table S2). 
Higher bilirubin levels predicted by the UGT1A1 SNP were weakly inversely associ-
ated with risk of ovarian cancer overall and serous ovarian cancer with ORs per 1-SD 
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increment equal to 0.96 (95% CI 0.92–1.00) and 0.94 (95% CI 0.90–0.98), respectively. In 
contrast, we observed a positive association between bilirubin levels predicted by non-
UGT1A1 SNPs and risk of ovarian cancer overall and serous ovarian cancer with ORs per 
1-SD increment equal to 1.10 (95% CI 1.00–1.21) and 1.12 (95% CI 1.00–1.24), respectively 
(Figure 1C, Figure S3A,B). However, these associations were attenuated toward the null 
after removing SNPs (n = 22) with potential pleiotropy. Furthermore, the MR-Egger Simex 
approach did not confirm the positive association suggested by the non-UGT1A1 SNPs 
(Table S2). 
Suggestive positive associations were observed between bilirubin levels, genetically 
predicted by non-UGT1A1 SNPs, and risk of breast cancer (Figure 1C). 
There was little evidence for associations between genetically raised bilirubin levels 
by either instrument and cancers of the endometrium (Figure 1C and Figure S3C–F) or 
prostate (Figure 1C and Figure S4). 
Finally, higher bilirubin levels predicted by the non-UGT1A1 SNPs were inversely 
associated with risk of Hodgkin’s lymphoma (OR 0.64, 95% CI 0.42–0.99) (Figure 1D and 
Figure S5A), while null results were observed for melanoma or neuroblastoma risk (Fig-
ure 1D and Figure S5B–C). 
 
Figure 1. Forest plot of associations between genetically-predicted bilirubin levels and risk of ten cancers (per one-stand-
ard deviation (1-SD) increment in circulating total bilirubin levels equivalent to ≈ 4.4 µmol/L). (A): The association between 
1-SD increment in bilirubin levels predicted by UGT1A1 SNP and the non-UGT1A1 SNPs with risks of pancreatic cancer 
and renal cell carcinoma (overall, men, and women). (B): The association between 1-SD increment in bilirubin levels pre-
dicted by UGT1A1 SNP and the non-UGT1A1 SNPs with risk of lung cancer (overall, ever smoker, never smoker, adeno-
carcinoma, squamous cell, and small cell lung cancers. (C): The association between 1-SD increment in bilirubin levels 
predicted by UGT1A1 SNP and the non-UGT1A1 SNPs with risks of ovarian cancer (overall and serous), breast cancer 
(overall, ER positive, and ER negative), endometrial cancer, and prostate cancer. (D): The association between 1-SD incre-
ment in bilirubin levels predicted by UGT1A1 SNP and the non-UGT1A1 SNPs with risks of Hodgkin’s lymphoma, mela-
noma, and neuroblastoma.The results are provided by a likelihood-based MR test, *with the exception of endometrial 
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cancer, which results are provided by the Egger-MR test. Abbreviations: OR odds ratio, CI confidence interval, p p -value, 
ER estrogen receptor. 
Sensitivity Analyses 
The IVW risk estimates performed almost identical to the main likelihood-based risk 
estimates, as both methods rely on the same assumptions and suffer similarly from plei-
otropy. Outlier SNPs were detected by the MR-PRESSO test in some analyses; however, 
their presence was not biasing the initially estimated risk effects (pDistortion > 0.25) (Table 
S2). Additionally, the MR-Egger intercept test detected overall directional pleiotropy only 
in the case of endometrial cancer (pintercept = 4x10-4) and returned a potential positive asso-
ciation between bilirubin levels, predicted by non-UGT1A1 SNPs, and endometrial cancer 
(OR 1.37; 95% CI 0.99–1.89) (Figure 1C and Table S2). The weighted median and modal-
based approaches provided similar risk estimates as the MR-Egger test in the case of en-
dometrial cancer and as the likelihood-based MR method for the other tested cancer types 
(Table S2). Finally, we identified a group of bilirubin SNPs that were genome-wide asso-
ciated with other phenotypes, such as educational attainment, body mass index, and mean 
corpuscular volume of red blood cells. The MR analyses after removing these SNPs with 
potential pleiotropy (n = 20 to 22 depending on GWAS data for specific cancer types) at-
tenuated associations of most of the ten cancers investigated, except for squamous cell 
lung cancer (OR 0.80, 95% CI 0.65–0.99), breast cancer (OR 1.12, 95% CI 1.04–1.20), and 
Hodgkin’s lymphoma (OR 0.61, 95% CI 0.32–1.14) (Table S2). 
4. Discussion 
In this hypothesis-driven two-sample MR study, we investigated potential causal as-
sociations between genetically raised circulating bilirubin levels, a purported endogenous 
antioxidant, and risk of cancers of the pancreas, renal cell, endometrium, ovary, breast, 
prostate, lung, Hodgkin’s lymphoma, melanoma, and neuroblastoma. We found that ge-
netically raised bilirubin concentrations were inversely associated with risk of squamous 
cell lung cancer and Hodgkin’s lymphoma, which is compatible with the antioxidant hy-
pothesis of bilirubin, but positively associated with risk of breast cancer. 
4.1. Lung Cancer 
The observed inverse association between genetically raised bilirubin levels and lung 
cancer risk among ever smokers, but not among never smokers, in our study are congru-
ent with a prospective study in the UKB [14]. Similar inverse associations were also ob-
served between serum bilirubin levels and the risk of lung cancer among male smoker in 
a Korean cohort (N cases = 240) [47] and in a prospective cohort in US (N cases = 386) [48]. 
Furthermore, in our study, we observed a robust inverse association with risk of squa-
mous cell lung cancer subtype (OR 0.80, 95% CI 0.65–0.99 after excluding SNPs with po-
tential pleiotropy), which is known to be strongly related to smoking. Taken together, 
genetically raised bilirubin levels may confer an advantage in terms of protecting people 
exposed to smoke oxidants against lung cancer [14,49]. 
4.2. Hodgkin’s Lymphoma 
We observed robust inverse associations between genetically raised bilirubin levels 
and risk of Hodgkin’s lymphoma. 
Our study is the first linking bilirubin metabolism to Hodgkin’s lymphoma. Given 
that one of the hypothesized root causes of Hodgkin’s lymphoma is infection by Epstein–
Barr virus [50], bilirubin might play a role in inhibiting replication of the virus as sug-
gested for hepatitis C virus [51] and/or by balancing oxidative stress induced by Epstein–
Barr virus infection [52]. 
4.3. Breast Cancer and Other Hormone-Related Cancers 
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There was a suggestive positive association between bilirubin levels, genetically pre-
dicted by non-UGT1A1 SNPs, and risk of breast cancer, in particular of the ER positive 
subtype (OR 1.12, 95% CI 1.03–1.22 after removing potential pleiotropic SNPs). These as-
sociations were relatively robust to a range of sensitivity analyses (Table S2). A meta-anal-
ysis of retrospective case-control studies (N cases = 5746, N controls = 8365) suggested that 
the UGT1A1*28 allele 7/7 genotype is a potential risk factor for breast cancer in Caucasians 
[53]. Given that higher circulating levels of bilirubin can inhibit glucuronidation of estro-
gens (estradiol) into water-soluble molecules for excretion [54] suggests that higher bili-
rubin may affect these hormone-related cancers indirectly by interacting with the estrogen 
metabolism pathway. 
In contrast to breast cancer, bilirubin levels predicted by the UGT1A1 SNP were in-
versely associated with risk of ovarian cancer overall and serous ovarian cancer. If the 
inverse associations were genuine, then these findings are potentially consistent with a 
second-line antioxidant defense of raised bilirubin levels in the epithelial lining of the ova-
ries. Similar to lung cancer, oxidative stress is a critical factor in the initiation and devel-
opment of ovarian cancer [55]. We are not aware of other studies investigating either cir-
culating bilirubin levels or the UGT1A1 polymorphism in relation to ovarian cancer risk, 
and further studies are warranted. 
4.4. Pancreatic Cancer 
The findings for pancreatic cancer resemble the results of our previous two-sample 
MR study on the role of genetically raised bilirubin levels in colorectal cancer (CRC) using 
the same set of SNPs as instrumental variables [56]. We showed that bilirubin levels pre-
dicted by instrumental variables excluding the UGT1A1 SNP were inversely associated 
with risk of CRC, supporting our hypothesis of anti-oxidative and anti-inflammatory 
properties of bilirubin. However, among men, bilirubin levels predicted by the UGT1A1 
SNP were positively associated with risk of CRC, and we argued that this could indicate 
either pleiotropic effects but potentially also pro-oxidative effects of an elevated bilirubin 
distribution among individuals with GS. 
4.5. Other Cancers (Renal Cell Cancer, Prostate Cancer, Melanoma, and Neuroblastoma) 
We found no strong evidence for an association between genetically raised bilirubin 
levels and the risk of renal cell cancer, prostate cancer, melanoma, and neuroblastoma. 
Our study has several strengths. First, we used thousands of cases and controls from 
several large genetic consortia and published GWAS, which signified the largest and most 
comprehensive MR study on genetically raised bilirubin levels and cancer risk. Second, 
our MR assumptions were met, which were supported by our sensitivity methods and 
pleiotropic SNPs exclusion. Finally, common sources of bias in observational studies, in-
cluding residual confounding and reverse causation, were likely reduced. This study has 
some limitations, first, a potentially under-powered sample size for the non-UGT1A1 in-
struments to detect small effects in some cancers. For these cancers, associations can occur 
by chance, especially when using weak instruments and small samples, which is a phe-
nomenon known as weak instruments bias [57]. Second, we cannot completely rule out 
chance in explaining the weaker observed associations. However, we had a strong prior 
hypothesis based on biological plausibility. Third, we also stress that the genetic instru-
ments for bilirubin do not necessarily reflect life-long exposure. However, assuming that 
the association between the instruments and bilirubin is constant over time, then the MR 
estimate could be interpreted as an estimate of the averaged cumulative effect of bilirubin 
on cancer within the age range at inclusion. Fourth, although we applied several strategies 
to account for horizontal pleiotropy, we cannot test and exclude the possibility that the 
main UGT1A1 SNP affects cancer risk through pathways other than elevated bilirubin 
levels. There is a large region of linkage disequilibrium across the UGT1A locus that in-
cludes functional polymorphisms in UGT [58,59], which aside from bilirubin, also metab-
olize several xenobiotic and endogenous substances including (e.g., heterocyclic aromatic 
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amines, in well-done red meat) [56] or sex hormones [58]. Therefore, the observed differ-
ential associations of the UGT1A1 SNP across cancer types may also reflect the modulated 
metabolism of such substances with carcinogenic potential. We also acknowledge that 
GWAS of associations of genetic variants on chronic diseases can be prone to selection 
bias from surviving competing risk. Methods to assess genetic effects on chronic diseases 
are needed to account for competing risk before recruitment [60]. 
Finally, we were not able to analyze non-linear associations, which would necessitate 
individual-level data. However, a non-linear relationship between bilirubin levels and 
cancer was not previously observed [56]. 
5. Conclusions 
Genetically raised bilirubin levels were inversely associated with risk of squamous 
cell lung cancer as well as Hodgkin’s lymphoma, and positively association with risk of 
breast cancer. These findings should help in setting priorities in future research on biliru-
bin levels and cancer risk. If confirmed in other studies, bilirubin could be a promising 
marker to risk stratify individuals for more frequent screening of selected cancers. 
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